Skip to Main Content

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Conditions

Anus | Colon | Pancreas | Rectum | Phase I

Phase I

What is the purpose of this trial?

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors.

  • Trial with
    MedImmune, Inc
  • Start Date
    06/12/2016
  • End Date
    03/31/2019
Trial Image

For more information about this study, contact:

Karen Forman

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/22/2018
  • Study HIC
    #1505015949